Three mid-caps are trading at discounts while the market celebrates IPO filings and AI earnings this week, and each has something happening in the next two weeks that puts them back in the conversation.

You can get ahead of all three setups before Wednesday's earnings print, and next week's data drops change the picture.

Agriculture

The Mosaic Company (NYSE: MOS), one of the world's largest phosphate and potash producers, trades at around $22, against a DCF fair value of $39.74, representing a 45% discount near a 52-week low. Q1 was rough… a $258 million net loss, pulled phosphate guidance, and sulfur costs heading to $540 per ton in Q2. Nobody is pretending this is comfortable.

RBC Capital just upgraded to Outperform anyway, arguing that the phosphate margin depression from the Hormuz closure is unsustainable and that the value is real even if the timing is early. The 4.11% dividend pays you to wait while the cycle turns.

A 45% discount on a globally essential crop nutrient business with an analyst upgrade attached is the setup that tends to look obvious in hindsight.

RBC Upgrade Signals the Contrarian Case Is Building

RBC moved to Outperform specifically because sulfur-driven margin pain is a cycle, not a structural break. When input costs normalize, the margin recovery gets moving quickly, and the 52-week low becomes the entry you wish you had taken more seriously.

A 45% DCF Discount With a 4% Yield Changes the Risk-Reward Math

You are not buying into a thriving business right now. You are buying the cycle at a 45% discount to where the cash flows say this should trade, with a dividend keeping you compensated while you wait for the story to stop being ugly.

Healthcare

IQVIA Holdings (NYSE: IQV) has dropped nearly 24% year to date and trades around $171.50 against a DCF fair value of $314.78. The more conservative analyst framework puts fair value at $250, still a 37% gap. It is not cheap for one model. It is cheap on all of them.

This is a clinical research company coming out of a two-year spending freeze. Biotech funding dried up, CRO budgets stalled, and the stock paid the price. That is reversing. Backlog has grown for two consecutive quarters, RFP flow is ticking higher, and the free cash flow base of $2.06 billion tells you the business itself has never broken.

You are looking at a quality compounder priced like a problem that has already started solving itself.

Backlog Growth for Two Straight Quarters Tells You the Freeze Is Thawing

Two consecutive quarters of backlog expansion and rising RFP activity are not noise. They are the leading indicator of a revenue recovery that tends to show up in numbers well before sentiment adjusts to match it.

$2.06 Billion in Free Cash Flow Is Not a Broken Business

A company generating over $2 billion annually in free cash flow does not deserve a 46% discount. It got one because sentiment overshot during the spending slowdown, and that kind of mispricing in a quality business tends to correct once the cycle becomes impossible to ignore.

Consumer Discretionary

Abercrombie & Fitch (NYSE: ANF) is one of the cleaner earnings setups of the week. The forward PE sits at 6.61 against an industry average of 14.93 and it reports Wednesday before market open. Consensus is $1.28 EPS, down 19.5% year over year. That sounds rough until you remember this company beat estimates four quarters in a row, most recently by 10.28%.

The brand turnaround is still running, and Hollister has finally found its footing. Full-year EPS consensus sits at $10.68 on $5.48 billion in revenue, an 8.3% annual increase, which makes the 6.6x multiple look increasingly disconnected from what the business is actually delivering.

A guidance reiteration on Wednesday would be more than enough to move this from overlooked to very much noticed.

Four Straight Beats Give Wednesday's Print Real Structure

A consistent track record of outperforming estimates changes how you read a pre-earnings setup. With a 10.28% most recent surprise and a 6.6x forward PE, this is less of a guess and more of a setup with real odds behind it.

Half the Industry Multiple on 8% Annual EPS Growth Is the Case in One Line

The apparel sector trades at nearly 15x forward earnings. ANF trades at 6.6x while growing annual earnings at 8.3%. That gap does not stay wide forever once the numbers keep landing and the narrative finally catches up.

CarMax (NYSE: KMX) is on Morningstar's Q1 2026 top undervalued picks list for a reason, and the setup keeps getting more interesting. The stock trades around $39 to $49 against a GF Value of $73.91, a 47% discount, with Starboard Value holding a $350 million stake and two board nominations adding activist pressure to an already compelling valuation case. 

The used vehicle market is stabilizing, financing spreads are improving, and Stephens just raised its price target to $43, citing unit sales momentum. Buy in the $38 to $45 range and let the cycle and the activist pressure do the work together. 

The risk is that auto credit conditions deteriorate faster than the margin recovery thesis can absorb.

IQVIA Holdings (NYSE: IQV) is the clinical research compounder that the market has discounted well past where the underlying fundamentals justify. A 46% gap to DCF fair value and a 37% gap to the narrative analyst consensus of $250 sit alongside $2.06 billion in trailing free cash flow and a backlog that has been growing for two consecutive quarters. 

The CRO spending recovery from the 2024-2025 biotech funding freeze is underway, and biotech M&A acceleration feeds directly into outsourced research demand in a way that should show up in bookings before it shows up in revenue. 

This is a quality business at a cyclical trough price, and that combination tends to resolve toward the fundamentals over an 18 to 24 month window. The risk is that the biotech funding recovery stalls again before backlog growth converts to revenue.

Masco (NYSE: MAS) is on Morningstar's Q1 undervalued picks list, and the Q1 2026 results gave the thesis something real to work with. Plumbing Products revenue rose 15.1% year over year to $1.36 billion, EPS came in at $1.04 versus $0.87 a year ago, and the stock has gained 10.6% over the past month. 

Housing transaction volume is still sitting at multi-decade lows, which means any normalization in existing home turnover is pure upside for pull-through demand in fixtures, paint, and cabinets. 

At roughly 15x forward earnings with a sector-relative discount intact, the setup keeps improving. The risk is that the housing market stays frozen longer than the earnings recovery thesis requires.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any [blank] stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge